FR07C0017I2 - Anticorps anti-vegf - Google Patents

Anticorps anti-vegf

Info

Publication number
FR07C0017I2
FR07C0017I2 FR07C0017C FR07C0017C FR07C0017I2 FR 07C0017 I2 FR07C0017 I2 FR 07C0017I2 FR 07C0017 C FR07C0017 C FR 07C0017C FR 07C0017 C FR07C0017 C FR 07C0017C FR 07C0017 I2 FR07C0017 I2 FR 07C0017I2
Authority
FR
France
Prior art keywords
vegf
vegf antibodies
vitro
antibodies
inhobit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR07C0017C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/908,469 external-priority patent/US6884879B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FR07C0017I1 publication Critical patent/FR07C0017I1/fr
Application granted granted Critical
Publication of FR07C0017I2 publication Critical patent/FR07C0017I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Air Bags (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)
FR07C0017C 1997-04-07 2007-03-07 Anticorps anti-vegf Active FR07C0017I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83350497A 1997-04-07 1997-04-07
US08/908,469 US6884879B1 (en) 1997-04-07 1997-08-06 Anti-VEGF antibodies
EP98917991A EP0973804B1 (fr) 1997-04-07 1998-04-03 Anticorps anti-vegf

Publications (2)

Publication Number Publication Date
FR07C0017I1 FR07C0017I1 (fr) 2007-04-27
FR07C0017I2 true FR07C0017I2 (fr) 2008-05-09

Family

ID=27125626

Family Applications (2)

Application Number Title Priority Date Filing Date
FR05C0020C Active FR05C0020I2 (fr) 1997-04-07 2005-04-20 Anticorps anti-VEGF
FR07C0017C Active FR07C0017I2 (fr) 1997-04-07 2007-03-07 Anticorps anti-vegf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR05C0020C Active FR05C0020I2 (fr) 1997-04-07 2005-04-20 Anticorps anti-VEGF

Country Status (26)

Country Link
US (2) US7060269B1 (fr)
EP (4) EP1325932B9 (fr)
JP (1) JP3957765B2 (fr)
KR (2) KR100816621B1 (fr)
CN (1) CN100480269C (fr)
AT (2) ATE293640T1 (fr)
AU (1) AU743758B2 (fr)
BR (1) BRPI9809387B8 (fr)
CA (1) CA2286330C (fr)
CY (3) CY2005008I2 (fr)
DE (5) DE69829891T2 (fr)
DK (2) DK0973804T3 (fr)
ES (2) ES2273415T3 (fr)
FR (2) FR05C0020I2 (fr)
GE (1) GEP20105118B (fr)
HK (2) HK1023577A1 (fr)
IL (1) IL132240A0 (fr)
LT (1) LTPA2005005I1 (fr)
LU (2) LU91167I2 (fr)
NL (2) NL300193I2 (fr)
NO (3) NO324264B1 (fr)
NZ (1) NZ500078A (fr)
PT (1) PT1325932E (fr)
SI (1) SI1325932T1 (fr)
TR (1) TR199903123T2 (fr)
WO (1) WO1998045331A2 (fr)

Families Citing this family (490)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
WO2000034337A1 (fr) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Anticorps monoclonaux humanises luttant contre un facteur de croissance de cellules endotheliales vasculaires
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
NZ514918A (en) * 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
EP1203026A4 (fr) * 1999-07-29 2005-03-16 Dyax Corp Fractions se liant la fibrine
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
EP1757311B1 (fr) 1999-12-24 2009-02-11 Genentech, Inc. Méthodes et compositions pour la prolongation de la demi-période d'élimination de composés bioactifs
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP2077276A1 (fr) 2000-06-23 2009-07-08 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
EP2275549A1 (fr) 2000-06-23 2011-01-19 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
US6902718B2 (en) 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
WO2003066662A2 (fr) 2002-02-05 2003-08-14 Genentech, Inc. Purification de proteines
EP1501369B1 (fr) 2002-04-26 2015-06-24 Genentech, Inc. Purification de proteines basee sur la non affinite
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
BR0312692A (pt) 2002-07-15 2007-06-26 Univ Texas anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
CA2965865C (fr) 2002-07-18 2021-10-19 Merus N.V. Production par recombinaison de melanges d'anticorps
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2513113A1 (fr) * 2003-01-23 2004-08-05 Genentech, Inc. Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire
WO2004070016A2 (fr) 2003-02-03 2004-08-19 Fraunhofer Usa Inc. Systeme d'expression de genes dans des plantes
WO2004080418A2 (fr) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Composes d'acide nucleique pouvant inhiber l'angiogenese et la croissance tumorale
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
WO2005026375A2 (fr) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Molecule support recombinee pour l'expression, l'administration et la purification de polypeptides cibles
KR20160114727A (ko) 2003-05-30 2016-10-05 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (fr) * 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Banque de fab pour la preparation de fab anti-vegf et antirabique
ES2786568T3 (es) 2003-07-28 2020-10-13 Genentech Inc Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005012531A2 (fr) * 2003-08-01 2005-02-10 Genentech, Inc. Polypeptides de liaison avec sequences de diversite restreinte
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
ES2388138T3 (es) 2003-08-27 2012-10-09 Ophthotech Corporation Terapia de combinación para tratamiento de trastornos neovasculares oculares
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DE602005025459D1 (de) 2004-03-12 2011-02-03 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (fr) 2004-07-13 2006-11-30 Dexcom, Inc. Detecteur d'analyte
BRPI0513534A (pt) 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CN101048427B (zh) 2004-07-23 2015-01-14 健泰科生物技术公司 抗体或其片段的结晶
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
ES2529451T3 (es) 2004-09-23 2015-02-20 Vasgene Therapeutics, Inc. Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
WO2006047325A1 (fr) 2004-10-21 2006-05-04 Genentech, Inc. Methode de traitement de maladies neovasculaires intraoculaires
ZA200704934B (en) 2004-12-22 2010-09-29 Genentech Inc Methods for producing soluble multi-membrane-spanning proteins
JP5057994B2 (ja) * 2005-01-06 2012-10-24 ジーイー・ヘルスケア・アクスイェ・セルスカプ 光学イメージング
RU2452482C2 (ru) 2005-02-18 2012-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинация и способы введения терапевтических средств и комбинированной терапии
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2586459B1 (fr) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du VEGF
EP1879587A2 (fr) * 2005-04-15 2008-01-23 Schering Corporation Methodes et compositions pour le traitement ou la prevention du cancer
AU2006261357A1 (en) * 2005-06-17 2006-12-28 Zimmer Spine Austin, Inc. Improved method of treating degenerative spinal disorders
BRPI0622254A2 (pt) * 2005-06-20 2011-08-09 Genentech Inc anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
TWI429452B (zh) 2005-08-31 2014-03-11 Abraxis Bioscience Llc 包含弱水溶性藥劑及抗微生物劑之組合物
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
EP1959958A4 (fr) * 2005-11-14 2010-07-14 Univ Southern California Petites molecules de liaison a une integrine
AU2006323412A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
WO2007070671A2 (fr) † 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
US8101365B2 (en) 2006-01-05 2012-01-24 Genentech, Inc. Anti-EphB4 antibodies and methods using same
KR101617108B1 (ko) 2006-01-20 2016-04-29 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
KR20080106433A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
RS54156B1 (en) 2006-03-21 2015-12-31 Genentech Inc. COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS
CN101405030B (zh) * 2006-03-22 2013-03-13 霍夫曼-拉罗奇有限公司 针对血管内皮生长因子的抗体和针对人表皮生长因子2型受体的抗体在制备治疗肿瘤的试剂盒中的应用
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP2009531463A (ja) * 2006-03-29 2009-09-03 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
BRPI0710411A2 (pt) * 2006-06-06 2012-04-10 Genentch Inc Empresa Americana Métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4
BRPI0710413A2 (pt) 2006-06-06 2011-08-23 Genentech Inc anticorpos anti-dll4, isolados, polinucleotìdeo, vetor, célular hospedeira, método para produção de um anticorpo anti-dll4, método para produção de um imunoconjugado anti-dll4, método para a detecção de dll4, metodo para diagnosticar um distúrbio, composições, método para tratar um tumor, cáncer e/ou disturbio da proliferação celular e método para melhorar a eficácia de um agente anti-angiogênico
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
EP2068877A4 (fr) 2006-07-19 2011-09-21 Cleveland Clinic Foundation Composés et méthodes de modulation de l'angiogenèse
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用
CN101505792B (zh) 2006-08-21 2012-10-03 霍夫曼-拉罗奇有限公司 使用抗-vegf抗体的肿瘤疗法
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
PL2069798T3 (pl) 2006-10-04 2014-09-30 Genentech Inc Test ELISA dla VEGF
CN102006885A (zh) * 2006-10-20 2011-04-06 先灵公司 完全人源抗vegf抗体及其使用方法
KR20140031996A (ko) * 2006-12-19 2014-03-13 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
EP2125013A4 (fr) * 2007-01-26 2010-04-07 Bioinvent Int Ab Inhibiteurs de la signalisation dll4 et utilisations associees
AU2008216495A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
WO2008143665A1 (fr) 2007-05-17 2008-11-27 Genentech, Inc. Inhibition de métastases tumorales par des anticorps anti-neuropiline 2
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CA2692933C (fr) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Antigenes yersinia pestis, compositions de vaccins, et methodes associees
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
EP3492488A1 (fr) 2007-08-22 2019-06-05 The Regents of The University of California Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
ES2572958T3 (es) 2007-10-30 2016-06-03 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
TW200924796A (en) * 2007-11-09 2009-06-16 Genentech Inc Activin receptor-like kinase-1 compositions and methods of use
EP2219672B1 (fr) 2007-11-09 2016-02-17 Peregrine Pharmaceuticals, Inc. Compositions d'anticorps anti-vegf et procédés correspondants
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
PL2254571T3 (pl) 2008-03-18 2015-11-30 Genentech Inc Kombinacje koniugatu przeciwciała anty-HER2-lek i środki chemioterapeutyczne oraz sposoby zastosowania
JP5425180B2 (ja) * 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
EP2280997A2 (fr) * 2008-04-18 2011-02-09 Xencor, Inc. Anticorps monoclonaux d équivalent humain conçus à partir de régions variables non humaines
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
EP3002299A1 (fr) 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
WO2009151514A1 (fr) 2008-06-11 2009-12-17 Millipore Corporation Bioréacteur à cuve agitée
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
CN102149724B (zh) 2008-08-14 2014-04-09 健泰科生物技术公司 使用原地蛋白质置换离子交换膜层析清除污染物的方法
US20100055099A1 (en) * 2008-08-29 2010-03-04 Ellen Filvaroff Diagnostics and Treatments for VEGF-Independent Tumors
CA2736029A1 (fr) 2008-09-05 2010-03-11 Duke University Anticorps antilipidiques
KR20110076918A (ko) 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
PE20150682A1 (es) 2008-10-14 2015-05-20 Genentech Inc Variantes de inmunoglobulinas y sus usos
MX2011004649A (es) 2008-11-03 2011-05-30 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
ES2498274T3 (es) 2008-11-05 2014-09-24 Genentech, Inc. Polimorfismos genéticos en degeneración macular relacionada con la edad
MX340724B (es) 2008-11-22 2016-07-22 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama.
ES2749232T3 (es) 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
CA2746120A1 (fr) 2008-12-23 2010-07-01 Genentech, Inc. Procedes et compositions pour une utilisation diagnostique chez les patients atteints de cancer
EP3543256A1 (fr) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Compositions d anticorps modifiées et leurs procédés de production et d'utilisation
WO2010081838A2 (fr) 2009-01-14 2010-07-22 Novartis Ag Récipient stérile pré-rempli
CN102333544A (zh) 2009-02-06 2012-01-25 通用医疗公司 治疗血管损伤的方法
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
CN102333548B (zh) 2009-02-27 2013-01-30 健泰科生物技术公司 用于蛋白质标记的方法和组合物
BRPI1008955A2 (pt) 2009-03-13 2015-09-01 Abraxis Bioscience Llc Terapia de combinação com derivados de tiocolchicina.
WO2010111254A1 (fr) 2009-03-25 2010-09-30 Genentech, Inc. Nouveaux anticorps anti-α5β1 et leurs utilisations
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
MX2011010908A (es) * 2009-04-16 2012-02-21 Abbott Biotherapeutics Corp Anticuerpos anti-tnf-alfa y sus usos.
SG175289A1 (en) * 2009-04-20 2011-11-28 Genentech Inc Adjuvant cancer therapy
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2427479B1 (fr) 2009-05-07 2018-11-21 The Regents of The University of California Anticorps et procédés d'utilisation de ceux-ci
CA2665956A1 (fr) * 2009-05-07 2010-11-07 Samir Patel Traitement combine pour des maladies oculaires
KR101754433B1 (ko) 2009-05-08 2017-07-05 백시넥스 인코포레이티드 항-ｃｄ100 항체 및 이의 사용 방법
AR076662A1 (es) 2009-05-08 2011-06-29 Genentech Inc Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos
EP2443234B1 (fr) 2009-06-15 2018-08-15 Icon Genetics GmbH Plants de nicotinia benthamiana à activité xylosyltransférase déficiente
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG177640A1 (en) 2009-07-13 2012-02-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
AR078060A1 (es) 2009-07-14 2011-10-12 Novartis Ag Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
WO2011014457A1 (fr) 2009-07-27 2011-02-03 Genentech, Inc. Traitements d’association
CA2769308A1 (fr) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition de metastase tumorale utilisant des antagonistes de bv8 ou de g-csf
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
BR112012003077A2 (pt) 2009-08-14 2019-09-24 Genentech Inc mercadorias biologicas para monitorar resposta em paciente para antagonistas de vegf
AR077848A1 (es) 2009-08-15 2011-09-28 Genentech Inc Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado
RU2571929C2 (ru) 2009-09-01 2015-12-27 Дженентек, Инк. Улучшенная очистка белка посредством модифицированного элюирования белка а
US8642515B2 (en) 2009-09-04 2014-02-04 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
RU2012114094A (ru) 2009-09-11 2013-10-20 Дженентек, Инк. Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
WO2011034605A2 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
WO2011041391A1 (fr) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Anticorps dirigés contre l'hémagglutinine du virus de la grippe, compositions, et procédés associés
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
MY176035A (en) 2009-10-21 2020-07-22 Genentech Inc Genetic polymorphisms in age-related macular degeneration
WO2011056497A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
WO2011056502A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions du gene recepteur de proteine morphogenetique osseuse type ii et procedes d'utilisation
EP2509626B1 (fr) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anticorps anti-vegf-c et leurs procédés d'utilisation
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
MY161868A (en) 2009-12-23 2017-05-15 Genentech Inc Anti-bv8 antibodies and uses thereof
EP2695889A1 (fr) 2009-12-29 2014-02-12 Dr. Reddy's Laboratories Limited Purification des protéines par échange d'ions
WO2011095596A1 (fr) 2010-02-04 2011-08-11 Vivalis Procédé à alimentation discontinue utilisant un milieu de culture de cellules concentré pour la production efficace de produits biologiques dans des cellules eb66
UA114277C2 (uk) 2010-02-23 2017-05-25 Дженентек, Інк. Антиангіогенна терапія для лікування раку яєчника
KR101878369B1 (ko) 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
SI2552415T1 (sl) 2010-03-29 2017-03-31 Abraxis Bioscience, Llc Metode za zdravljenje raka
WO2011133521A2 (fr) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Traitement anticancéreux utilisant une combinaison de composés inhibiteurs de hsp90 et un inhibiteur de vegf
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
KR101551295B1 (ko) 2010-05-17 2015-09-08 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
CA2800728C (fr) 2010-05-28 2020-10-27 Genentech, Inc. Reduction du niveau de lactate et augmentation de la production de polypeptides par regulation negative de l'expression de la lactate deshydrogenase et de la pyruvate deshydrogena se kinase
WO2011153243A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac
WO2011153224A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Procédés diagnostiques et compositions de traitement du cancer
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CN103068367B (zh) 2010-06-24 2016-09-07 弗·哈夫曼-拉罗切有限公司 用于稳定含有蛋白质的制剂的含有烷基糖苷的组合物和方法
CN102958536A (zh) 2010-07-02 2013-03-06 基因泰克公司 用抗-vegf疗法治疗血管化色素上皮脱离
RU2571226C2 (ru) 2010-07-09 2015-12-20 Дженентек, Инк. Антитела против нейропилина и способы их применения
RU2013104039A (ru) 2010-07-19 2014-08-27 Ф. Хоффманн-Ля Рош Аг Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию
EP2824457A1 (fr) 2010-07-19 2015-01-14 F. Hoffmann-La Roche AG Méthode d'identification d'un patient présentant une probabilité accrue de répondre à un traitement anticancéreux
RU2013109275A (ru) 2010-08-03 2014-09-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
WO2012021773A1 (fr) 2010-08-13 2012-02-16 Genentech, Inc. Anticorps anti-il-1β et il-18, pour le traitement de maladies
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012030512A1 (fr) 2010-09-03 2012-03-08 Percivia Llc. Procédé de purification de protéine en flux
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR20130124513A (ko) 2010-11-15 2013-11-14 파이브 프라임 테라퓨틱스, 인크. 가용성 fgfr1 융합 단백질의 상승된 투약량에 의한 암 치료
EP2655413B1 (fr) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (fr) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps contre dll4 et leurs utilisations
WO2012095514A1 (fr) 2011-01-14 2012-07-19 Vivalis Système de production de protéines recombinantes
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
EP3138581B1 (fr) 2011-03-17 2019-01-02 The University of Birmingham Immunothérapie redirigée
EP2691417B1 (fr) 2011-03-29 2018-08-01 Roche Glycart AG Variants de fc d'anticorps
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
BR112013025353A8 (pt) 2011-04-01 2018-01-02 Genentech Inc combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
US9932386B2 (en) 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
US20140178398A1 (en) 2011-05-03 2014-06-26 Genentech, Inc Vascular disruption agents and uses thereof
WO2012172054A1 (fr) 2011-06-16 2012-12-20 Scil Proteins Gmbh Protéines d'ubiquitine multimères modifiées se liant au vegf-a
JP2014522843A (ja) 2011-06-30 2014-09-08 ジェネンテック， インコーポレイテッド 抗ｃ−ｍｅｔ抗体製剤
WO2013009767A2 (fr) 2011-07-12 2013-01-17 Epitomics, Inc. Procédé sur la base de facs pour obtention de séquence d'anticorps
EP2551348B1 (fr) 2011-07-29 2014-09-24 Icon Genetics GmbH Production de N-glycanes galactosylatées dans des plantes
WO2013025944A1 (fr) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition de l'angiogenèse dans les tumeurs réfractaires
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
WO2013050155A1 (fr) 2011-10-04 2013-04-11 Icon Genetics Gmbh Plantes nicotiana benthamiana déficientes dans l'activité fucosyltransférase
US20130095118A1 (en) 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
BR112014008819A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Métodos para o tratamento de síndrome de vazamento vascular e câncer
JP2014532072A (ja) * 2011-10-13 2014-12-04 エアピオ セラピューティックス， インコーポレイテッド 眼疾患の治療
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
EP2788026A4 (fr) 2011-12-05 2015-08-05 Univ Duke Immunogènes v1v2
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
WO2013091903A1 (fr) 2011-12-22 2013-06-27 Novo Nordisk A/S Anticorps anti-canal crac
SI2794635T1 (sl) 2011-12-22 2018-12-31 F. Hoffmann-La Roche Ag Ionskoizmenjevalna membranska kromatografija
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
EP2802346B1 (fr) 2012-01-13 2018-09-12 F.Hoffmann-La Roche Ag Marqueurs biologiques servant à identifier des patients pour un traitement avec des antagonistes du vegf
WO2013119966A2 (fr) 2012-02-10 2013-08-15 Genentech, Inc. Anticorps et autres hétéromultimères monocaténaires
US9475840B2 (en) 2012-02-27 2016-10-25 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
CA3056813A1 (fr) 2012-03-13 2013-09-19 F. Hoffmann-La Roche Ag Polytherapie pour le traitement d'un cancer de l'ovaire
MY171729A (en) 2012-03-27 2019-10-25 Genentech Inc Improved harvest operations for recombinant proteins
JP6335875B2 (ja) 2012-03-30 2018-05-30 ジェネンテック， インコーポレイテッド 癌の治療のための診断法及び組成物
MX360110B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
WO2013170182A1 (fr) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Traitement d'un cancer au moyen d'un composé inhibiteur de hsp90
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
SG10201603055WA (en) 2012-05-31 2016-05-30 Genentech Inc Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
KR102386843B1 (ko) 2012-06-01 2022-04-15 노파르티스 아게 시린지
WO2013182668A1 (fr) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Sélectivité mutante et associations d'un inhibiteur de phospho‑inositide 3 kinase et agents chimiothérapeutiques pour le traitement du cancer
BR112014032193A2 (pt) 2012-06-27 2017-06-27 Hoffmann La Roche métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
CN104411718B (zh) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
EP3495387B1 (fr) 2012-07-13 2021-09-01 Roche Glycart AG Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le traitement des maladies vasculaires oculaires
SG11201500903XA (en) 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
RU2681928C2 (ru) 2012-09-19 2019-03-13 Дженентек, Инк. Способы и композиции для предотвращения ошибки включения норлейцина в белки
US20140227252A1 (en) 2012-10-31 2014-08-14 Oncomed Pharmaceuticals , Inc. Methods and Monitoring of Treatment with a DLL4 Antagonist
RU2017137740A (ru) 2012-11-01 2019-02-11 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
WO2014074218A1 (fr) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Composés et procédés pour produire un conjugué
EP2920148B1 (fr) 2012-11-16 2019-06-12 The Regents of the University of California Ligature pictet-spengler pour la modification chimique de protéines
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
UY35195A (es) 2012-12-18 2014-07-31 Novartis Ag Composiciones y metodos para proteinas de accion prolongada
WO2014100095A1 (fr) 2012-12-19 2014-06-26 Genentech, Inc. Procédés et compositions pour le marquage de protéine par un radiohalogène
AU2014205369B2 (en) 2013-01-11 2018-08-09 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
WO2014118643A2 (fr) 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Procédés visant à induire une réactivité à un agent anti-angiogénique
RU2699007C2 (ru) 2013-02-18 2019-09-02 Ведженикс Пти Лимитед Молекулы, связывающие лиганды, и их применение
MY185551A (en) 2013-03-13 2021-05-19 Genentech Inc Antibody formulations
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US9441035B2 (en) 2013-03-15 2016-09-13 Genentech, Inc. Cell culture media and methods of antibody production
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA2904806C (fr) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Anticorps modifies se liant au fcrn humain et procedes d'utilisation
MX2015015426A (es) 2013-05-23 2016-06-10 Five Prime Therapeutics Inc Metodos de tratamiento de cancer.
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
JP6611709B2 (ja) 2013-06-25 2019-11-27 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
CN110193009A (zh) 2013-07-12 2019-09-03 伊维希比奥公司 用于治疗或预防眼科病的方法
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
HUE052447T2 (hu) 2013-09-08 2021-04-28 Kodiak Sciences Inc A VIII. tényezõs zwitterionos polimer konjugációk
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
CN105899225A (zh) 2013-10-25 2016-08-24 阿塞勒隆制药公司 用于治疗纤维化疾病的内皮联蛋白肽
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
WO2015081282A1 (fr) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
MX2015014724A (es) * 2013-12-31 2016-06-02 Dev Center Biotechnology Anticuerpos anti-factor de crecimiento endotelial vascular (vegf) y uso de los mismos.
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10100115B2 (en) 2014-02-14 2018-10-16 Macrogenics, Inc. Methods for the treatment of vascularizing cancers
WO2015124588A1 (fr) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de maladies induites par la voie de signalisation du complexe nrp-1/obr
EP3110941A4 (fr) 2014-02-25 2017-10-18 Dr. Reddy's Laboratories Ltd. Procédé de modification de la galactosylation et de la teneur en g0f d'une composition de glycoprotéine par un apport complémentaire en glutamine
WO2015135884A1 (fr) 2014-03-10 2015-09-17 Richter Gedeon Nyrt. Purification d'immunoglobuline à l'aide d'étapes de pré-nettoyage
HUE048531T2 (hu) 2014-03-14 2020-07-28 Novartis Ag Antitest molekulák a LAG-3-hoz és ezek felhasználása
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
EP3492495A1 (fr) 2014-05-12 2019-06-05 Formycon AG Seringue en plastique préremplie contenant un antagoniste de vegf
EP3760229A3 (fr) 2014-05-15 2021-04-07 Bristol-Myers Squibb Company Traitement du cancer du poumon à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux
JP6668260B2 (ja) 2014-06-06 2020-03-18 レッドウッド バイオサイエンス， インコーポレイテッド 抗ｈｅｒ２抗体−メイタンシンコンジュゲート及びその方法
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (fr) 2014-06-25 2017-05-03 Novartis AG Compositions et procédés permettant d'obtenir des protéines à action prolongée
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
CN106460067A (zh) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 诊断方法和用于治疗成胶质细胞瘤的组合物
CA2957717C (fr) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Traitement tumoral synergique a l'aide d'il-2 et d'une proteine de fusion fc liant l'integrine
WO2016025647A1 (fr) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Traitement tumoral synergique avec l'il-2, un anticorps thérapeutique, et un vaccin contre le cancer
CN105330739B (zh) * 2014-08-12 2020-12-25 中美华世通生物医药科技（武汉）有限公司 与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
ES2949173T3 (es) 2014-09-15 2023-09-26 Hoffmann La Roche Formulaciones de anticuerpo
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TN2017000129A1 (en) 2014-10-14 2018-10-19 Dana Farber Cancer Inst Inc Antibody molecules to pd-l1 and uses thereof
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
EP3209769B1 (fr) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions et procédés pour induire la phagocytose de cellules positives de classe i du cmh et pour contrer la résistance aux agents anti-cd47/sirpa
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
CA2960297A1 (fr) 2014-11-10 2016-05-19 Genentech, Inc. Anticorps anti-interleukine 33 et leurs utilisations
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
ES2907148T3 (es) 2014-12-11 2022-04-22 Bayer Healthcare Llc Tratamiento de la degeneración macular asociada a la edad con una pequeña lesión de neovascularización coroidea activa
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016106340A2 (fr) 2014-12-23 2016-06-30 Genentech, Inc. Compositions et méthodes destinées à traiter et à diagnostiquer des cancers résistant à la chimiothérapie
WO2016120753A1 (fr) * 2015-01-28 2016-08-04 Pfizer Inc. Formulation aqueuse stable d'anticorps anti-facteur de croissance endothélial vasculaire
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
EP3286315B1 (fr) 2015-04-24 2021-05-26 F. Hoffmann-La Roche AG Procédés d'identification de bactéries comprenant des polypeptides de liaison
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
CA2988420A1 (fr) 2015-06-08 2016-12-15 Genentech, Inc. Methodes destinees a traiter le cancer a l'aide d'anticorps anti-ox40 et d'antagonistes se liant a l'axe pd-1
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP2018522887A (ja) 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
US10266589B2 (en) 2015-07-29 2019-04-23 Allergan, Inc. Heavy chain only antibodies to ANG-2
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
WO2017019897A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Polythérapies comprenant des molécules d'anticorps contre tim -3
HU231463B1 (hu) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
US10308711B2 (en) 2015-08-14 2019-06-04 Allergan, Inc. Heavy chain only antibodies to PDGF
EP3337508A4 (fr) * 2015-08-21 2019-04-03 Immunomedics, Inc. Anticorps monoclonal anti-hla-dr à administrer par voie sous-cutanée pour le traitement de tumeurs malignes hématologiques
CA2994888A1 (fr) 2015-09-17 2017-03-23 Immunogen, Inc. Combinaisons therapeutiques comprenant des immunoconjugues anti-folr1
WO2017046140A1 (fr) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne
DK3353196T3 (da) 2015-09-22 2023-02-20 Inst Nat Sante Rech Med Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
KR20180053315A (ko) 2015-09-23 2018-05-21 제넨테크, 인크. 항-vegf 항체의 최적화된 변이체들
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
WO2017055325A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules nk dans un prélèvement de tissu
WO2017055319A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules b dans un prélèvement de tissu
WO2017055327A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules endothéliales dans un échantillon de tissu
WO2017055322A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de neutrophiles dans un prélèvement de tissu
WO2017055320A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de quantification de la population de lymphocytes cytotoxiques dans un prélèvement de tissu
WO2017055321A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de fibroblastes dans un prélèvement de tissu
WO2017055326A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules dendritiques myéloïdes dans un prélèvement de tissu
WO2017055324A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu
EP3362095B1 (fr) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et préparations pharmaceutiques pour le traitement de la neovascularisation choroidienne
EP3368565A1 (fr) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Formulations d'anticorps anti-facteur d
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
ES2870141T3 (es) 2015-10-30 2021-10-26 Hoffmann La Roche Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
WO2017079112A1 (fr) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Anticorps se liant spécifiquement à pd-1 et leurs utilisations
US20190209697A1 (en) 2015-11-05 2019-07-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
WO2017087798A1 (fr) 2015-11-18 2017-05-26 Formycon Ag Conditionnement pharmaceutique prérempli comprenant une formulation liquide d'un antagoniste du vegf
WO2017087871A1 (fr) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Emballage pharmaceutique pour formulations ophtalmiques
CA3005692A1 (fr) 2015-11-18 2017-05-26 Formycon Ag Seringue en plastique preremplie contenant un antagoniste du facteur de croissance de l'endothelium vasculaire (vegf)
AU2016364817B2 (en) 2015-12-03 2020-05-07 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
JP6953433B2 (ja) 2016-01-26 2021-10-27 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
CA3019373A1 (fr) 2016-03-29 2017-10-05 Geltor, Inc. Expression de proteines dans des bacteries gram negatif, avec un rapport du volume periplasmique au volume cytoplasmique compris entre 0,5:1 et 10:1
EP3443120A2 (fr) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Méthodes de surveillance et de traitement du cancer
CA3019921A1 (fr) 2016-04-15 2017-10-19 Genentech, Inc. Methodes de suivi et de traitement du cancer
BR112018073781A2 (pt) 2016-05-20 2019-02-26 Biohaven Pharmaceutical Holding Company Ltd. uso de agentes de modulação de glutamato com imunoterapias para o tratamento de câncer
CN109890982B (zh) 2016-07-08 2023-07-07 基因泰克公司 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
EP3482205A1 (fr) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Utilisation de la protéine 4 d'épididyme humaine (he4) pour évaluer la sensibilité à un traitement d'un cancer positif pour muc16
WO2018011166A2 (fr) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules dendritiques myéloïdes dans un échantillon de tissu
MX2019000727A (es) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
WO2018018613A1 (fr) 2016-07-29 2018-02-01 广东东阳光药业有限公司 Milieu de culture et procédé de culture cellulaires pour augmenter la pureté d'un anticorps
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
MX2019001635A (es) 2016-08-12 2019-06-10 Genentech Inc Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
WO2018037001A1 (fr) * 2016-08-23 2018-03-01 Medimmune Limited Anticorps anti-vegf-a et leurs utilisations
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
JP2020505438A (ja) 2017-01-10 2020-02-20 ノダス・セラピューティクスＮｏｄｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ インテグリン結合性ポリペプチド−Ｆｃ融合タンパク質および免疫調節物質を用いる併用がん治療法
WO2018160841A1 (fr) 2017-03-01 2018-09-07 Genentech, Inc. Procédés diagnostiques et thérapeutiques relatifs au cancer
EP3601332A1 (fr) * 2017-03-24 2020-02-05 Council of Scientific and Industrial Research Procédé de purification de fragments d'anticorps recombinants
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
MX2019013750A (es) 2017-05-19 2020-07-20 Council Scient Ind Res Un metodo para producir ranibizumab humanizado recombinante replegado.
WO2018217995A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Conditionnements pharmaceutiques pré-remplis stérilisables comprenant une formulation liquide d'un antagoniste du vegf
WO2018215580A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf
CA3063995A1 (fr) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Conditionnement pharmaceutique sterilisable pour formulations ophtalmiques
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
CU24606B1 (es) 2017-06-22 2022-06-06 Novartis Ag Moléculas de anticuerpo que se unen a cd73
EP3642240A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
US11931327B2 (en) 2017-07-04 2024-03-19 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
WO2019020777A1 (fr) 2017-07-26 2019-01-31 Formycon Ag Formulation liquide d'un antagoniste du vegf
WO2019057946A1 (fr) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Composés aromatiques multi-cycliques utilisés en tant qu'inhibiteurs du facteur d
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US20210322574A1 (en) 2017-10-20 2021-10-21 Vascular Biogenics Ltd. Diagnostic methods for anti-angiogenic agent therapy
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
EP3731864A1 (fr) 2017-12-29 2020-11-04 F. Hoffmann-La Roche SA Anticorps anti-vegf et procédés d'utilisation
CN110003328B (zh) * 2018-01-05 2022-04-19 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
IL276383B2 (en) 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmological diseases
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
AU2019254237A1 (en) 2018-04-16 2020-12-03 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
JOP20200303A1 (ar) 2018-05-24 2020-11-23 Janssen Biotech Inc عوامل ربط psma واستخداماتها
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019229116A1 (fr) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Administration intravitréenne d'un polypeptide de décorine pour le traitement de la néovascularisation choroïdienne
WO2019232244A2 (fr) 2018-05-31 2019-12-05 Novartis Ag Molécules d'anticorps anti-cd73 et leurs utilisations
WO2020006509A1 (fr) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antagonistes antitumoraux
SG11202012582QA (en) 2018-07-03 2021-01-28 Bristol Myers Squibb Co Methods of producing recombinant proteins
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
MA53859A (fr) 2018-10-10 2022-01-19 Boehringer Ingelheim Int Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
CA3116324A1 (fr) 2018-10-18 2020-04-23 Genentech, Inc. Procedes de diagnostic et de therapie pour le cancer sarcomatoide du rein
HUP1800376A2 (hu) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
WO2020109343A1 (fr) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Polythérapie pour le traitement de la dégénérescence maculaire
CN109134651B (zh) * 2018-12-03 2019-02-22 上海复宏汉霖生物技术股份有限公司 一种抗vegf的单克隆抗体及其制备方法和应用
US20200207812A1 (en) 2018-12-07 2020-07-02 Coherus Biosciences, Inc. Methods for producing recombinant proteins
CN113226472A (zh) 2018-12-17 2021-08-06 雷维托普有限公司 双免疫细胞衔接物
MX2021011084A (es) 2019-03-13 2021-10-22 Vascular Biogenics Ltd Metodos de terapia antitumoral.
SG11202110043TA (en) 2019-04-01 2021-10-28 Genentech Inc Compositions and methods for stabilizing protein-containing formulations
HU231498B1 (hu) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelõzõ flokkulálás alkalmazásával
EP3953380A4 (fr) 2019-04-12 2023-01-25 Geltor, Inc. Élastine de recombinaison et production associée
MA55717A (fr) 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
CN114269376A (zh) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 用抗pd-l1抗体治疗癌症的方法
EP3965816A1 (fr) 2019-05-06 2022-03-16 MedImmune Limited Combinaison de monalizumab, de durvalumab, de chimiothérapie et de bévacizumab ou de cétuximab pour le traitement du cancer colorectal
WO2020263312A1 (fr) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFβ1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
KR20220039777A (ko) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4041312A4 (fr) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
WO2021072210A1 (fr) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Procédés de purification de ranibizumab ou d'un variant de ranibizumab
WO2021072182A1 (fr) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Procédés de production de ranibizumab
WO2021100034A1 (fr) 2019-11-19 2021-05-27 Protalix Ltd. Élimination de constructions à partir de cellules transformées
IL293241A (en) 2019-11-25 2022-07-01 Akeso Biopharma Inc Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
US11760797B2 (en) 2020-03-13 2023-09-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2023520515A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド がんに対する治療方法及び診断方法
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
PE20231093A1 (es) 2020-07-16 2023-07-18 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
US20230357815A1 (en) 2020-09-22 2023-11-09 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
US20230374447A1 (en) 2020-10-05 2023-11-23 Protalix Ltd. Dicer-like knock-out plant cells
IL302089A (en) 2020-10-15 2023-06-01 Hoffmann La Roche Non-covalent protein-hyaluronan conjugates for long-term ocular delivery
MX2023005529A (es) 2020-11-13 2023-05-25 Genentech Inc Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos.
EP4255570A1 (fr) 2020-12-01 2023-10-11 Akouos, Inc. Constructions d'anticorps anti-vegf et procédés associés pour le traitement de symptômes associés au neurinome de l'acoustique
EP4281102A1 (fr) 2021-01-22 2023-11-29 Mendus B.V. Procédés de vaccination antitumorale
WO2022162518A2 (fr) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Protéines de liaison à psma et leurs utilisations
CA3193662A1 (fr) 2021-03-12 2022-09-15 Akeso Biopharma, Inc. Combinaison pharmaceutique contenant un anticorps bispecifique anti-pd-1-anti-vegfa, et son utilisation
CA3212351A1 (fr) 2021-03-12 2022-09-15 Mendus B.V. Methodes de vaccination et utilisation d'un blocage de cd47
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
WO2022247917A1 (fr) 2021-05-28 2022-12-01 上海瑞宏迪医药有限公司 Virus adéno-associé recombinant ayant une capside variante, et son application
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
AU2022302170A1 (en) 2021-07-02 2023-12-21 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
KR20240038008A (ko) 2021-07-28 2024-03-22 에프. 호프만-라 로슈 아게 암 치료 방법 및 조성물
WO2023015234A1 (fr) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Procédés de culture cellulaire pour la production de protéines thérapeutiques
WO2023016516A1 (fr) 2021-08-13 2023-02-16 信达生物制药(苏州)有限公司 Anticorps bispécifique anti-vegf a et anti-vegf c et son utilisation
EP4145456A1 (fr) 2021-09-06 2023-03-08 Bayer AG Prédiction d'un changement relatif à un fluide maculaire
WO2023049687A1 (fr) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Procédés de régulation du taux d'oxygène dissous (do) dans une solution comprenant une protéine recombinante dans un récipient de stockage
WO2023080900A1 (fr) 2021-11-05 2023-05-11 Genentech, Inc. Procédés et compositions pour classer et traiter le cancer rénal
AR128422A1 (es) 2022-02-02 2024-05-08 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
WO2024040175A1 (fr) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Méthodes de traitement du cancer au moyen d'un inhibiteur de l'angiogenèse inhalé
CN117679505A (zh) 2022-09-09 2024-03-12 中山康方生物医药有限公司 药物组合及用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JPS6289971A (ja) * 1985-06-13 1987-04-24 Toray Ind Inc 静電潜像用液体現像剤
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2345497A1 (fr) * 1988-10-28 1990-04-28 Genentech, Inc. Variantes de l'hormones de croissance et procede de fabrication des variantes de l'hormone de croissance
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2082160C (fr) * 1991-03-06 2003-05-06 Mary M. Bendig Anticorps monoclonaux humanises et chimeriques
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
CA2128862C (fr) 1992-02-11 2008-05-20 Jonathan G. Seidman Obtention de cellules homozygotes par recombinaison homologue
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DK1167384T3 (da) * 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
DK0971959T3 (da) * 1997-04-07 2006-05-15 Genentech Inc Humaniserede antistoffer og fremgangsmåder til dannelse af humaniserede antistoffer
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper

Also Published As

Publication number Publication date
ATE293640T1 (de) 2005-05-15
EP1787999B1 (fr) 2010-08-04
NL300278I1 (nl) 2007-06-01
CN100480269C (zh) 2009-04-22
NL300193I1 (nl) 2005-07-01
DE69836729D1 (de) 2007-02-08
BRPI9809387B8 (pt) 2021-05-25
NO994869D0 (no) 1999-10-06
DE69829891T2 (de) 2005-10-06
AU7100798A (en) 1998-10-30
CY2005008I1 (el) 2009-11-04
JP3957765B2 (ja) 2007-08-15
ATE349470T1 (de) 2007-01-15
EP1325932A2 (fr) 2003-07-09
BR9809387A (pt) 2001-09-11
LU91167I2 (fr) 2005-06-20
DE122005000026I1 (de) 2005-08-04
EP0973804B1 (fr) 2006-12-27
CA2286330C (fr) 2008-06-10
SI1325932T1 (fr) 2005-08-31
DE122005000050I1 (de) 2005-12-29
LTPA2005005I1 (lt) 2017-11-27
DE122007000021I1 (de) 2007-05-24
KR100816621B1 (ko) 2008-03-24
US7297334B2 (en) 2007-11-20
NO2007015I2 (fr) 2011-11-28
FR05C0020I2 (fr) 2008-05-09
EP1650220A2 (fr) 2006-04-26
KR20080003453A (ko) 2008-01-07
EP1325932B1 (fr) 2005-04-20
EP1650220B1 (fr) 2007-09-05
FR07C0017I1 (fr) 2007-04-27
IL132240A0 (en) 2001-03-19
DE69829891D1 (de) 2005-05-25
NO324264B1 (no) 2007-09-17
DK1325932T5 (da) 2005-10-03
CN1259962A (zh) 2000-07-12
ES2273415T3 (es) 2007-05-01
CY1106382T1 (el) 2010-07-28
NO2007014I2 (no) 2011-02-21
US20050112126A1 (en) 2005-05-26
KR20080003452A (ko) 2008-01-07
NO2007014I1 (no) 2008-01-14
EP1325932A3 (fr) 2003-10-29
CA2286330A1 (fr) 1998-10-15
NL300193I2 (nl) 2005-10-03
CY2005008I2 (el) 2017-11-14
CY2007012I1 (el) 2009-11-04
BRPI9809387B1 (pt) 2016-11-22
CY2007012I2 (el) 2009-11-04
EP0973804A2 (fr) 2000-01-26
HK1023577A1 (en) 2000-09-15
KR100870353B1 (ko) 2008-11-25
PT1325932E (pt) 2005-06-30
LU91320I2 (fr) 2007-04-30
NO994869L (no) 1999-12-06
AU743758B2 (en) 2002-02-07
NL300278I2 (nl) 2007-10-01
TR199903123T2 (xx) 2000-05-22
DE69836729T2 (de) 2007-12-13
US7060269B1 (en) 2006-06-13
DK1325932T3 (da) 2005-05-30
WO1998045331A3 (fr) 1998-12-03
ES2236634T3 (es) 2005-07-16
DK0973804T3 (da) 2007-05-07
WO1998045331A2 (fr) 1998-10-15
EP1325932B9 (fr) 2006-07-19
HK1084402A1 (en) 2006-07-28
JP2001509817A (ja) 2001-07-24
EP1650220A3 (fr) 2006-05-03
GEP20105118B (en) 2010-11-25
NO2007015I1 (no) 2008-01-14
NZ500078A (en) 2001-10-26
FR05C0020I1 (fr) 2005-05-27
EP1787999A1 (fr) 2007-05-23
LU91320I9 (fr) 2018-12-31

Similar Documents

Publication Publication Date Title
NO2019045I1 (no) Ranibizumab - Forlenget SPC
FR07C0017I2 (fr) Anticorps anti-vegf